NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 8 December 9:00am

**Location:** Zoom Video Conference

## Attendees

Committee members present

1. Professor Amanda Adler (Chair) Present for all items
2. Dr Sanjeev Patel (Vice Chair) Present for all items
3. Ms Anna Pracz Present for all items
4. Dr Charles Crawley Present for all items
5. Mr Gabriel Rogers Present for all items
6. Ms Denise Bryceland Present for all items
7. Dr James Fotheringham Present for all items
8. Dr Laura Bojke Present for all items
9. Dr Mark Glover Present for all items
10. Ms Mary Weatherstone Present for all items
11. Dr Nicholas Latimer Present for all items
12. Professor Nicky Welton Present for all items
13. Mr Nigel Westwood Present for all items
14. Peter Wheatley Price Present for all items
15. Dr Rhiannon Owen Present for all items
16. Professor Sarah Wild Present for all items
17. Dr Stuart Williams Present for all items
18. Mr Tony Wootton Present for all items

NICE staff present

James Devine, Coordinator Present for all items

Laura Marsden, Public involvement Present for items 1 to 3.1.3, 4 to

advisor 4.1.3, 5 to 5.1.3

Ewa Rupniewska, Health technology Present for all items

assessment advisor

Janet Robertson, Associate Present for items 1 to 3.3

director

Thomas Feist, Project manager Present for items 1 to 3.3

Henry Edwards, Associate director Present for all 4 to 4.3

Daniel Davies, Project manager Present for items 5 to 5.3

Louise Jones, Administrator Present for items 1 to 3.3

George Braileanu, Technical lead Present for items 1 to 3.3

Eleanor Donegan, Technical advisor Present for items 1 to 3.3

Shonagh D’Sylva, Project manager Present for items 4 to 4.3

Sharlene Ting, Technical lead Present for items 4 to 4.3

Carl Prescott, Technical advisor Present for items 4 to 4.3

Richard Diaz, Associate director Present for items 5 to 5.3

Emma Gordon, Administrator Present for items 5 to 5.3

Heather Stegenga, Technical lead Present for items 5 to 5.3

Adam Brooke, Technical advisor Present for items 5 to 5.3

Lizzie Coates, Scientific advisor Present for all items

James Love-Koh, Scientific advisor Present for all items

Emily Eaton-Turner, Technical analyst, Present for all items

commercial risk assessment

Ella Livingstone, Technical analyst Present for all items

commercial risk assessment

Evidence review group representatives present:

Jeremy Howick, Kleijnen Systematic Present for items 1 to 3.1.3

Reviews

Bram Ramaekers, Kleijnen Systematic Present for items 1 to 3.1.3

Reviews

Rita Faria, York Centre for Reviews Present for items 4 to 4.1.3

and Dissemination

Mark Rodgers, York Centre for Reviews Present for items 4 to 4.1.3

and Dissemination

James Mahon, Liverpool Reviews and Present for items 5 to 5.1.3

Implementation Group (LRIG)

Sophie Beale, Liverpool Reviews and Present for items 5 to 5.1.3

Implementation Group

Patient & clinical experts present:

Mr Guy Hill, Patient expert Present for items 1 to 3.1.3

Prof. Jonathan Barratt, Clinical expert Present for items 1 to 3.1.3

Prof. Sunil Bhandari, Clinical expert Present for items 1 to 3.1.3

Daniel Cairns, Patient expert Present for items 4 to 4.1.3

Huw Stiley, Patient expert Present for items 4 to 4.1.3

Dr Jennifer Pinney, Clinical expert Present for items 4 to 4.1.3

Dr Carol Whelan, Clinical expert Present for items 4 to 4.1.3

Dr Charlotte Manisty, clinical expert Present for items 4 to 4.1.3

Dr Natalie Charney, Clinical expert Present for items 5 to 5.1.3

Dr Richard Griffiths, Clinical expert Present for items 5 to 5.1.3

Sophie-Ann Scott, Patient expert Present for items 5 to 5.1.3

Jennifer Vaughn, Patient expert Present for items 5 to 5.1.3

Company representatives present

Mahmood Ali, Astellas pharma Present for items 1 to 3.1.3

Ailie Roberts, Astellas pharma Present for items 1 to 3.1.3

Cristina Penaloza, Janssen & Present for items 4 to 4.1.3

Cilag ltd

Zeyad Khalef, Janssen & Present for items 4 to 4.1.3

Cilag ltd

Sophia Ho, Bristol Myers Squibb Present for items 5 to 5.1.3

Andrew Clark, Bristol Myers Squibb Present for items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Carlo Berti, Professor Iolo Dull, Ms Maria Brezitski, Dr Stephen Smith, Dr Toby Smith, and Dr Veline L’Esperance.

### News and announcements

* 1. None.

### Appraisal of Appraisal of Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from Astellas Pharma.
     2. The chair asked all committee members, clinical and patient experts, and external group representatives, to declare any relevant interests in relation to the item being considered.
* Professor Jonathan Barratt, clinical expert, declared the following interest: *I have received payments from Astellas Pharma for speaking engagements and sitting on advisory boards. Also lecture fees from GSK.* - It was agreed that this declaration would not prevent him from taking part in this discussion.
* Professor Sunil Bhandari, clinical expert, declared the following interests: *I have honorarium for lecturing and attending advisory boards from companies who produce medications for treating anaemia of chronic kidney disease including Astellas. I also sat on Astra Zeneca Advisory board and GlaxoSmithKline advisory board in relation to HIF stabilizers*  
  - It was agreed that these declarations would not prevent him from taking part in this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by James Fotheringham (clinical effectiveness lead), Nicky Welton (cost lead), and Nigel Westwood (lay lead).
  1. Part 2 – Closed session (company representatives, professional experts, and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
  2. Further updates will be available on the NICE webpage in due course:

https://www.nice.org.uk/guidance/indevelopment/gid-ta10610

### Appraisal of Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Janssen & Cilag Ltd.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nicholas Latimer declared the following interests: *I am the member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are listed as a comparator company.*- It was agreed that these declarations would not prevent him from participating in this discussion
* James Fotheringham declared the following interests: *I chaired a session ran by Janssen & Cilag Ltd at the British Transplant Society on transplant outcome prediction in March 2021 I participated in an advisory board meeting about transplant outcome measures in July 2021ScHARR did two activities which I was involved in. We compiled the briefing book for the NICE scientific advisory meeting Novartis had in 2020. This work completed in around August 2020. We reviewed their early health economic model for iscalimab (which they have stopped the trial for due to inferiority) in August 2021*- It was agreed that these declarations would not prevent him from participating in this discussion, but that he would not be a voting committee member on this topic.
* Huw Stiley, one of the attending patient experts, declared the following interests: *Amyloidosis UK, the charity he was nominated by, represents AL Amyloidosis patients.*- It was agreed that this declaration would not prevent him from participating in this discussion.
  + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley (costing lead), Sanjeev Patel (clinical lead), and Tony Wootton (lay advisor)
  1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course:

https://www.nice.org.uk/get-involved/meetings-in-public/technology-appraisal-committee

### Appraisal of Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma (CDF review of TA581) [ID3880]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Bristol Myers Squibb.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Richard Griffiths, clinical expert, declared the following interest: *I have received speaker and consultancy fees from BMS in the last 12 months*  
  - It was agreed that this declaration would not prevent him from participating in this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Laura Bojke (costing lead), Charles Crawley (clinical lead), and Nigel Westwood (lay lead).
  1. Part 2a – Closed session (members of the public and company representatives were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (evidence review group members were asked to leave the meeting).
     1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course:

https://www.nice.org.uk/guidance/indevelopment/gid-ta10854

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 20 January 2022 and will start promptly at 09:00am.